Candel Therapeutics IPO

Developer of cancer immunotherapies designed to improve the lives of cancer patients and their families. The company's immunotherapies focus on preventing the recurrence and progression of cancer with low toxicity level which is well suited for the treatment of less aggressive or slower growing cancers such as newly diagnosed prostate cancer, enabling physicians to ensure improved outcomes for their patients and help them recover faster.

Register for Details

For more details on financing and valuation for Candel Therapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

What is Candel Therapeutics's ticker symbol?


What is Candel Therapeutics's stock price?

1.13 as of 9/20/23

Learn more about Candel Therapeutics

Forge green plus iconForge green minus icon

What is Candel Therapeutics funding to date?

Candel Therapeutics has raised $67.6MM to date.
Updated on: Jun 12, 2022